Compare · ARGX vs REPL
ARGX vs REPL
Side-by-side comparison of argenx SE (ARGX) and Replimune Group Inc. (REPL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and REPL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 70.7x REPL ($782.0M).
- REPL has been more active in the news (13 items in the past 4 weeks vs 5 for ARGX).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Replimune Group Inc.
- Price
- $881.90-1.11%
- $8.94-5.60%
- Market cap
- $55.32B
- $782.0M
- 1M return
- +12.02%
- -
- 1Y return
- +51.11%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 5
- 13
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest REPL
- Chief Commercial Officer Sarchi Christopher sold $110,880 worth of shares (12,000 units at $9.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 180,962 units (SEC Form 4)
- Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- Replimune upgraded by Analyst with a new price target
- Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
- SEC Form SCHEDULE 13G filed by Replimune Group Inc.
- Chief Medical Officer Xynos Konstantinos sold $71,237 worth of shares (14,023 units at $5.08), decreasing direct ownership by 6% to 235,662 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Schwendenman Andrew sold $40,102 worth of shares (7,894 units at $5.08), decreasing direct ownership by 7% to 107,057 units (SEC Form 4) to cover taxes
- Chief Commercial Officer Sarchi Christopher sold $43,820 worth of shares (8,626 units at $5.08), decreasing direct ownership by 4% to 192,962 units (SEC Form 4) (for tax liability)